Article thumbnail

HIV Protease Inhibitors Act as Competitive Inhibitors of the Cytoplasmic Glucose Binding Site of GLUTs with Differing Affinities for GLUT1 and GLUT4

By Richard C. Hresko and Paul W. Hruz

Abstract

The clinical use of several first generation HIV protease inhibitors (PIs) is associated with the development of insulin resistance. Indinavir has been shown to act as a potent reversible noncompetitive inhibitor of zero-trans glucose influx via direct interaction with the insulin responsive facilitative glucose transporter GLUT4. Newer drugs within this class have differing effects on insulin sensitivity in treated patients. GLUTs are known to contain two distinct glucose-binding sites that are located on opposite sides of the lipid bilayer. To determine whether interference with the cytoplasmic glucose binding site is responsible for differential effects of PIs on glucose transport, intact intracellular membrane vesicles containing GLUT1 and GLUT4, which have an inverted transporter orientation relative to the plasma membrane, were isolated from 3T3-L1 adipocytes. The binding of biotinylated ATB-BMPA, a membrane impermeable bis-mannose containing photolabel, was determined in the presence of indinavir, ritonavir, atazanavir, tipranavir, and cytochalasin b. Zero-trans 2-deoxyglucose transport was measured in both 3T3-L1 fibroblasts and primary rat adipocytes acutely exposed to these compounds. PI inhibition of glucose transport correlated strongly with the PI inhibition of ATB-BMPA/transporter binding. At therapeutically relevant concentrations, ritonavir was not selective for GLUT4 over GLUT1. Indinavir was found to act as a competitive inhibitor of the cytoplasmic glucose binding site of GLUT4 with a KI of 8.2 µM. These data establish biotinylated ATB-BMPA as an effective probe to quantify accessibility of the endofacial glucose-binding site in GLUTs and reveal that the ability of PIs to block this site differs among drugs within this class. This provides mechanistic insight into the basis for the clinical variation in drug-related metabolic toxicity

Topics: Research Article
Publisher: Public Library of Science
OAI identifier: oai:pubmedcentral.nih.gov:3179492
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2004). A structural basis for the acute effects of HIV protease inhibitors on GLUT4 intrinsic activity.
  2. (2005). Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study.
  3. (1998). Cell-surface biotinylation of GLUT4 using bis-mannose photolabels.
  4. (1998). Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. New England
  5. (1989). Differential regulation of two distinct glucose transporter species expressed in 3T3-L1 adipocytes: effect of chronic insulin and tolbutamide treatment.
  6. (1991). Differential sorting of two glucose transporters expressed in insulin-sensitive cells.
  7. (2005). Direct comparison of the acute in vivo effects of HIV protease inhibitors on peripheral glucose disposal.
  8. (2006). Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity: demonstrable differences in vitro and clinically.
  9. (2010). Effects of the HIV protease inhibitor ritonavir in GLUT4 knockout mice.
  10. (2005). Evaluation of Enzyme Inhibitors in Drug Discovery A Guide for Medicinal Chemists and Pharmacologists.
  11. (2011). Exenatide improves glucose homeostasis and prolongs survival in a murine model of dilated cardiomyopathy.
  12. (1990). Exofacial photolabelling of the human erythrocyte glucose transporter with an azitrifluoroethylbenzoyl-substituted bismannose.
  13. (2000). Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection.
  14. (2002). Indinavir inhibits the glucose transporter isoform Glut4 at physiologic concentrations.
  15. (2003). Indinavir uncovers different contributions of GLUT4 and GLUT1 towards glucose uptake in muscle and fat cells and tissues.
  16. (1990). Insulin-responsive glucose transporters are concentrated in a cell surface-derived membrane fraction of 3T3-L1 adipocytes.
  17. (1992). Klip A
  18. (2005). Metabolic syndrome and cardiovascular disease in patients with human immunodeficiency virus.
  19. (2011). Molecular mechanisms for insulin resistance in treated HIVinfection.
  20. (2001). Structural analysis of the GLUT1 facilitative glucose transporter (review).
  21. (2004). The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults.
  22. (2001). The HIV protease inhibitor indinavir decreases insulin- and contraction-stimulated glucose transport in skeletal muscle.
  23. (1989). The kinetics and thermodynamics of glucose transport in human erythrocytes: indications for the molecular mechanism of transport.
  24. (2000). The mechanism of insulin resistance caused by HIV protease inhibitor therapy.
  25. (2006). Tipranavir without ritonavir does not acutely induce peripheral insulin resistance in a rodent model.